

THE APPLICABILITY OF MOLECULAR HYDROGEN IN THE TREATMENT OF NEURODEGENERATIVE DISEASES: A BIBLIOGRAPHICAL REVIEW

Edis Rodrigues Junior¹

Juliana Oliveira de Toledo²

Abstract: Introduction: This article discusses the growing research on the use of molecular hydrogen (H₂) in the treatment of neurodegenerative diseases, such as Alzheimer's, Parkinson's and Amyotrophic Lateral Sclerosis (ALS). H₂ stands out for its antioxidant and anti-inflammatory properties, which can reduce oxidative stress and inflammation in the brain, key factors in the progression of these diseases. Objective: To review current studies on the applicability of molecular hydrogen as a neuroprotective therapy, exploring its effects and possible benefits in the treatment of neurodegenerative diseases. Methodology: A literature review was carried out based on scientific articles published in the last 10 years in the PubMed, Scielo and ScienceDirect databases. Inclusion criteria included clinical and preclinical studies investigating molecular hydrogen as a therapeutic agent. Discussion: Studies indicate that H₂ can act in the neutralization of free radicals, modulation of the cellular redox state and reduction of inflammation, which contributes to neuroprotection. Several administration methods are analyzed, such as inhalation, H₂-enriched water, and injections. Clinical trials suggest improvements in cognitive function and reduction in the progression of neurodegenerative diseases, but research is still needed to establish optimal doses and more detailed mechanisms of action. Conclusion: Molecular hydrogen has great therapeutic potential for neurodegenerative diseases, being safe and low-cost. However, more clinical studies are needed to validate its efficacy and define treatment protocols.

1 CEP-HM Hydrogen Max Study and Research Center

2 AbmDF-Biomedical Association of the Federal District



Keywords: Molecular hydrogen, neuroprotection, oxidative stress.

Introduction

In the last decade, research on therapies for neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS), has expanded significantly due to the increasing prevalence of these diseases in the world population (FALCO, 2016). Although pharmacological treatments exist, most have limited efficacy and adverse effects that are sometimes not tolerated by patients, greatly reducing the cost-benefit of treatment. Molecular hydrogen (H₂), due to its antioxidant and anti-inflammatory properties, emerges as a promising alternative for complementary treatments. (SARAMAGO, 2018).



Molecular hydrogen (H₂) has emerged as a therapy with great potential in the treatment of neurodegenerative diseases, such as Alzheimer's, Parkinson's and Amyotrophic Lateral Sclerosis (ALS). Its application in neurodegenerative conditions has been intensively studied, as H₂ has significant antioxidant and anti-inflammatory properties that can protect the brain from damage caused by oxidative stress and chronic inflammation — common and aggravating processes in many of these diseases.

In terms of mechanism of action, it is a flammable, colorless, odorless, and water-insoluble gas, which can easily cross cell membranes, including the blood-brain barrier, allowing its direct arrival to brain tissue. (CAMPUS, 2018). One of the main ways of its action is the neutralization of



free radicals, such as the hydroxyl radical and the superoxide anion, which are highly reactive and toxic to neuronal cells.

In addition, H₂ can modulate the cellular redox state, increasing the expression of endogenous antioxidants and improving the balance between the pro and antioxidant systems, which is essential for the protection of neural cells. (BARBOSA, 2010)

In addition to antioxidant action, molecular hydrogen also exerts anti-inflammatory effects by reducing the release of pro-inflammatory cytokines such as TNF- α and IL-6, which are often elevated in neurodegenerative diseases. This helps decrease chronic brain inflammation, which contributes to the progressive death of neurons and cognitive decline. (CAPITA, 2024)

Methods of applying molecular hydrogen in therapies include its inhalation, oral administration through H₂-enriched water, and injections, depending on the clinical need and the desired degree of absorption. Preclinical studies and trials early clinical findings indicate that molecular hydrogen administration may contribute to improved cognitive function, decreased motor symptoms, and slowed the progression of neurodegenerative diseases, especially when integrated with other therapeutic approaches. (FALCO, 2016)

Inhalation of H₂ gas is the simplest and most widely used form. Inhaled H₂ diffuses into the alveoli of the lungs and is transported by blood throughout the body. On the other hand, the ingestion of water dissolved in H₂ (HW)* is considered safer and more convenient. Studies have shown that drinking water saturated with H₂ can prevent arteriosclerosis in animal models. However, the injection of H₂-dissolved saline (HS) is used in specific clinical settings and varies depending on the disease.

Studies so far suggest that the administration of H₂ has significant clinical potential for the prevention, treatment, and mitigation of neurological disorders such as neurodegenerative diseases and ischemic brain injuries. No adverse effects of H₂ have been reported, and it is considered relatively easy to use, cost-effective, and effective in daily medical practice. However, more research is still needed to establish the optimal dose and route of administration for each disease, as well as elucidate the mechanisms molecular effects that underpin the biological effects of H₂. (IKETANI, 2017)



This paper aims to review current studies on molecular hydrogen, addressing its therapeutic properties and its applicability in neuroprotection.

Methodology

For the construction of this review, a search was carried out in the main scientific databases (PubMed, Scielo, ScienceDirect) using the terms: “molecular hydrogen”, “neurodegenerative diseases”, “Alzheimer’s”, “Parkinson’s”, “neuroprotection”. The inclusion criteria were clinical and preclinical studies published in the last 10 years, which addressed molecular hydrogen as a therapeutic agent. We excluded opinion articles and studies of poor methodological quality.

Discussion

The use of molecular hydrogen (H₂) as a treatment for degenerative diseases such as Alzheimer’s, Parkinson’s, and Amyotrophic Lateral Sclerosis (ALS) has attracted increasing attention in scientific research due to its potential antioxidant and anti-inflammatory properties. However, it is important to note that despite initial promises, widespread implementation and clinical use are still in the early stages. (TORRÃO, 2012)

According to SEO, the study investigated the effects of consuming hydrogen-rich water (HW) compared to ordinary water (PW) on biological antioxidant potential (BAP) and markers of oxidative damage in humans. The research is motivated by growing evidence that oxidative stress

It plays a crucial role in various diseases and molecular hydrogen may have antioxidant properties.



Conclusion

Consumption of hydrogen-rich water can increase biological antioxidant potential and reduce oxidative damage in humans, especially in individuals aged 30 years and older. These results suggest that hydrogen-rich water may be an effective intervention to improve antioxidant health.

Ingestion of 1.5 L of H₂ water for 4 weeks reduced cell death and inflammatory responses by modulating the transcriptional networks of TLR-NFκB signaling. In addition, it may promote biological antioxidant capacity in adults > 30 years older than in younger individuals. (YES, 2020)

Alzheimer's and Parkinson's

In the case of Alzheimer's and Parkinson's, several experimental and clinical studies have explored H₂ for its neuroprotective properties. Studies have suggested that H₂ may help reduce oxidative stress, a key factor in the progression of these diseases. H₂ has shown potential in animal model studies and in preliminary clinical trials. In the treatment of Alzheimer's, some studies indicate that H₂ may have a protective effect on neurons, potentially helping to reduce inflammation and oxidation in the brain.

The mechanism of action of molecular hydrogen H₂ is quite interesting and multifaceted, acting mainly as an antioxidant, helping to neutralize free radicals in the body, which are unstable molecules that can cause oxidative stress and cell damage. Specifically, H₂ has the ability to selectively reduce the most toxic free radicals, such as hydroxyl radicals (•OH) and hydrogen peroxide (H₂O₂), without affecting beneficial free radicals that play important roles in physiological processes.

In addition to its antioxidant properties, H₂ may also influence several cell signaling pathways. Studies suggest that it may regulate the expression of genes related to oxidative stress and inflammation, promoting a healthier cellular environment. For example, hydrogen gas inhalation has shown positive effects in models of neurodegenerative diseases, such as Parkinson's and Alzheimer's



disease, possibly through the reduction of oxidative stress and modulation (JOHNSEN, 2023)

In the treatment of Parkinson's, H₂ has shown promise in reducing oxidative stress in dopaminergic neurons, which are characteristically affected by Parkinson's. Research shows that H₂ exerts neuroprotective effects, particularly in models of cerebral ischemia-reperfusion. The administration of H₂ was associated with reduced neuronal damage, due to its ability to inhibit the production of ROS and reactive nitrogen species (RNS), preserving cellular integrity. (LI, 2020)

According to YORITAKA ET AL, 2013 a pilot study was a randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy of water dissolved in molecular hydrogen (H₂) in Japanese patients with Parkinson's disease (PD) medicated with levodopa. Participants were 18 patients, with a mean age of 62.7 years, 11 of whom were women. Participants were divided into two groups: one group received 1,000 mL/day of H₂ water and the other group received placebo water for 48 weeks. The group that consumed H₂ water showed a significant improvement in the total scores of the Unified Parkinson's Disease Rating Scale (UPDRS), with a median of -21.0 and a mean of -25.7±8.4. The placebo group showed worsening in the total UPDRS scores, with a median of 4.5 and a mean of 4.1±9.2. The difference between the groups was statistically significant (P<0.05).

H₂ water intake was safe and well tolerated. There was a significant improvement in total UPDRS scores in the group that consumed H₂ water, indicating a potential therapeutic benefit for PD patients.

The study participants were taking the following antiparkinsonian medications:



Drug	Number of patients using the medication
Levodopa (L-dopa)	
Dopamine agonists	7 patients in the placebo group and 5 in the H ₂ group
Anticholinergic agents	2 patients in each group
Selegiline	1 patient in the placebo group and 4 in the H ₂ group
Entacapona	2 patients in the placebo group and none in the H ₂ group
Amantadine	1 patient in each group
Zonisamide	1 patient in the placebo group and 5 in the H ₂ group

None of the patients changed treatment with L-dopa or other antiparkinsonian drugs during the study period.

The study suggests that longer trials with larger numbers of participants are needed to confirm these findings.

Amyotrophic Lateral Sclerosis (ALS)

In the context of ALS, some experimental studies suggest that H₂ may help reduce neuronal cell death, a mechanism that occurs in ALS, due to its ability to neutralize free radicals. However, despite some initial trials being promising, the amount of clinical data and large-scale studies is still small. (BARBOSA, 2010)

Although the exact mechanisms of action of molecular hydrogen are not completely understood, its ability to cross the blood-brain barrier and reach the central nervous system is an important differentiator. The modulation of oxidative stress and anti-inflammatory activity suggest that H₂ may be beneficial as an adjunct treatment in neurodegenerative diseases. However, the heterogeneity of the studies, the variable dosages, and the different methodologies limit the comparability of the results, highlighting the need for more robust clinical trials to confirm the effects in humans.

The results of the randomized controlled trial that looked at consuming 2 liters per day of alkaline ionized water for 8 weeks showed a decrease in markers of oxidative stress, as well as



improvements in participants' quality of life and physical performance. However, it is essential to note that the concentration of molecular hydrogen (H₂) has not been reported, only the oxidation-reduction potential (ORP), which is not a reliable indicator of dissolved H₂ concentration. This means that it is not possible to determine whether the positive results were actually attributed to the consumption of water with a high concentration of H₂ or if they were influenced by other factors. (CHEN, 2021)

Furthermore, in another study that tested the effects of different pH levels on diabetic patients, it was observed that only the group that consumed water with a high concentration of H₂ showed significant benefits, while the group with a low concentration of H₂, despite having an alkaline pH, did not show positive results. This highlights the importance of measuring H₂ concentration to validate the biological effects of ERW and avoid misinterpretations of the data. Therefore, the results suggest that the effectiveness of ERW is closely linked to the concentration of H₂ present in the water consumed. (LeBaron, 2022)

Conclusion

Molecular hydrogen presents a promising therapeutic profile for the treatment of neurodegenerative diseases, offering the potential to improve the quality of life of patients and reduce the progression of symptoms. However, more research is needed to establish administration protocols, effective dosages, and understand the specific mechanisms of action in the central nervous system. Thus, molecular hydrogen emerges as a complementary, safe, and low-cost treatment option that can potentially improve quality of life and slow the progression of neurodegenerative diseases.

However, more research is needed to define optimal dosages, treatment timing, and protocols to ensure their efficacy and safety in different patient populations. However, larger, long-term clinical trials are needed to confirm these findings and determine whether it may be a viable treatment option. However, the results are still inconclusive and more studies are needed to confirm the efficacy and safety of H₂ in these cases. In terms of statistics, the clinical use of H₂ for the treatment of these



diseases is still limited.

Most studies are in the preclinical investigation phase or small clinical trials, with few H₂-based therapies being officially approved by regulatory agencies in large markets, such as the FDA (USA) or EMA (European Union). There are some alternative hydrogen-based therapies, such as H₂ inhalers or hydrogenated water, but widespread use and clinical acceptance are still a long way off. According to some scientific societies, such as the International Society for Molecular Hydrogen Therapy (IHMS), although research is growing, H₂ as a clinical treatment for neurodegenerative diseases still needs more robust evidence to become an established practice.

Bibliographic Reference

BARBOSA, K. B. F. et al.. Estresse oxidativo: conceito, implicações e fatores modulatórios. *Revista de Nutrição*, v. 23, n. 4, p. 629–643, jul. 2010

CAMPOS, E. V. O uso de hidrogênio molecular pode reduzir a citotoxicidade do radical hidroxil em meio aquoso? *Investigação combinada de dinâmica molecular e teoria do estado de transição.*(2018)

CHEN, W., Zhang, HT. & Qin, SC. Neuroprotective Effects of Molecular Hydrogen: A Critical Review. *Neurosci. Bull.* 37, 389–404 (2021). <https://doi.org/10.1007/s12264-020-00597-1>

FALCO, A. D. et al.. DOENÇA DE ALZHEIMER: HIPÓTESES ETIOLÓGICAS E PERSPECTIVAS DE TRATAMENTO. *Química Nova*, v. 39, n. 1, p. 63–80, jan. 2016.

IKETANI, Masumi; OHSAWA, Ikuroh. Molecular hydrogen as a neuroprotective agent. *Current Neuropharmacology*, v. 15, n. 2, p. 325, 2017. DOI: 10.2174/1570159X14666160607205

JOHNSEN, H. M., Hiorth, M., & Klaveness, J. (2023). Molecular Hydrogen Therapy—A Review on Clinical Studies and Outcomes. *Molecules*, 28(23), 7785. <https://doi.org/10.3390/molecules28237785>

LEBARON, T. W., Sharpe, R., & Ohno, K. (2022). Electrolyzed–Reduced Water: Review I. Molecular Hydrogen Is the Exclusive Agent Responsible for the Therapeutic Effects. *International Journal of*



Molecular Sciences, 23(23), 14750. <https://doi.org/10.3390/ijms232314750>

LI P, Chen G, Dong X. The role of molecular hydrogen in cardiovascular protection. *J Cardiovasc Pharmacol.* 2020;76(1):45-55.

SARAMAGO, Eduardo Alves. O hidrogênio molecular potencializa a hipotermia e previne a hipotensão e a febre durante a inflamação sistêmica induzida por LPS. 2018. Dissertação (Mestrado em Fisiologia) - Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 2018. doi:10.11606/D.17.2019.tde-07022019-140036. Acesso em: 2025-01-27.

SIM, M., Kim, CS., Shon, WJ. et al. Hydrogen-rich water reduces inflammatory responses and prevents apoptosis of peripheral blood cells in healthy adults: a randomized, double-blind, controlled trial. *Sci Rep* 10, 12130 (2020). <https://doi.org/10.1038/s41598-020-68930-2>

TORRÃO, A. S. et al.. Different approaches, one target: understanding cellular mechanisms of Parkinson's and Alzheimer's diseases. *Brazilian Journal of Psychiatry*, v. 34, p. s194–s205, out. 2012.

YORITAKA A, Takanashi M, Hirayama M, Nakahara T, Ohta S, Hattori N. Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial. *Mov Disord.* 2013 Jun;28(6):836-9. doi: 10.1002/mds. 25375. Epub 2013 Feb 11. PMID: 23400965.

ZAIKA, C.The Role of Molecular Hydrogen in the Modulation of Oxidative and Inflammatory Processes in the Human Body: A Review of Its Therapeutic Effects. *Revista Científica Ipedss.* Volume 4. Número 2. 2024 e-ISSN 2764-4006 DOI 1055703

